{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T17:05:31Z","timestamp":1785863131920,"version":"3.56.0"},"reference-count":17,"publisher":"MDPI AG","issue":"19","license":[{"start":{"date-parts":[[2022,9,22]],"date-time":"2022-09-22T00:00:00Z","timestamp":1663804800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Japanese Society for Promotion of Science","award":["21KK0156"],"award-info":[{"award-number":["21KK0156"]}]},{"name":"Japanese Society for Promotion of Science","award":["22K16679"],"award-info":[{"award-number":["22K16679"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Background: Primary central nervous system lymphomas (PCNSLs) are sensitive to chemotherapy. The standard treatment is high-dose methotrexate (MTX)-based chemotherapy. There are no reports of successful treatment of acute uric acid nephropathy with rasburicase after MTX administration in PCNSLs. Case presentation: A 54-year-old man with a history of gout presented with a change in character and cognitive dysfunction. MRI showed a large enhancing mass spanning the bilateral frontal lobes and the right temporal lobe. After endoscopic biopsy, an MTX, procarbazine, and vincristine (MPV) regimen was initiated for the treatment of the PCNSL. After the initiation of chemotherapy, the patient experienced a gout attack, and blood examination revealed acute renal failure (ARF) and hyperuricemia. The considered causes of ARF included MTX toxicity and acute uric acid nephropathy. As the dramatic effect of MTX was observed, treatment was continued despite ARF, most probably due to acute hyperuricemia due to tumor lysis, which was treated in parallel. After an improvement in renal function, MTX was resumed, and rasburicase was initiated to control hyperuricemia. A complete response was obtained after induction chemotherapy. Hyperuricemia was controlled with rasburicase, and renal function was preserved. Conclusions: Acute uric acid nephropathy should be considered when ARF occurs after the initiation of MTX in PCNSLs, especially in newly diagnosed PCNSL patients with large tumors or hyperuricemia.<\/jats:p>","DOI":"10.3390\/jcm11195548","type":"journal-article","created":{"date-parts":[[2022,9,22]],"date-time":"2022-09-22T05:33:14Z","timestamp":1663824794000},"page":"5548","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Successful Treatment of Acute Uric Acid Nephropathy with Rasburicase in a Primary Central Nervous System Lymphoma Patient Showing a Dramatic Response to Methotrexate\u2014Case Report"],"prefix":"10.3390","volume":"11","author":[{"given":"Yoshihiro","family":"Mouri","sequence":"first","affiliation":[{"name":"Department of Neurosurgery, Brain Research Institute, Niigata University, Niigata 951-8585, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3098-8323","authenticated-orcid":false,"given":"Manabu","family":"Natsumeda","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Brain Research Institute, Niigata University, Niigata 951-8585, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noritaka","family":"Okubo","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Brain Research Institute, Niigata University, Niigata 951-8585, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taro","family":"Sato","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Brain Research Institute, Niigata University, Niigata 951-8585, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taiki","family":"Saito","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Brain Research Institute, Niigata University, Niigata 951-8585, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kohei","family":"Shibuya","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Brain Research Institute, Niigata University, Niigata 951-8585, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiori","family":"Yamada","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Brain Research Institute, Niigata University, Niigata 951-8585, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5887-7153","authenticated-orcid":false,"given":"Jotaro","family":"On","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Brain Research Institute, Niigata University, Niigata 951-8585, Japan"},{"name":"Department of Pathology, Brain Research Institute, Niigata University, Niigata 951-8585, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshihiro","family":"Tsukamoto","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Brain Research Institute, Niigata University, Niigata 951-8585, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9151-8184","authenticated-orcid":false,"given":"Masayasu","family":"Okada","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Brain Research Institute, Niigata University, Niigata 951-8585, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Makoto","family":"Oishi","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Brain Research Institute, Niigata University, Niigata 951-8585, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takeyoshi","family":"Eda","sequence":"additional","affiliation":[{"name":"Division of Pharmacy, Medical and Dental Hospital, Niigata University, Niigata 951-8520, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junko","family":"Murai","sequence":"additional","affiliation":[{"name":"Institute for Advanced Biosciences, Keio University, Tsuruoka 997-0052, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Shimizu","sequence":"additional","affiliation":[{"name":"Department of Pathology, Brain Research Institute, Niigata University, Niigata 951-8585, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4244-0277","authenticated-orcid":false,"given":"Akiyoshi","family":"Kakita","sequence":"additional","affiliation":[{"name":"Department of Pathology, Brain Research Institute, Niigata University, Niigata 951-8585, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yukihiko","family":"Fujii","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Brain Research Institute, Niigata University, Niigata 951-8585, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,9,22]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.1038\/bjc.2011.357","article-title":"Age, gender, and racial differences in incidence and survival in primary CNS lymphoma","volume":"105","author":"Villano","year":"2011","journal-title":"Br. J. Cancer"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.critrevonc.2017.03.019","article-title":"Primary central nervous system lymphoma","volume":"113","author":"Citterio","year":"2017","journal-title":"Crit. Rev. Oncol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1007\/s11912-018-0666-1","article-title":"Updates on Primary Central Nervous System Lymphoma","volume":"20","author":"Schaff","year":"2018","journal-title":"Curr. Oncol. Rep."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"797","DOI":"10.2176\/nmc.oa2013-0195","article-title":"Advantages of Dose-dense Methotrexate Protocol for Primary Central Nervous System Lymphoma: Comparison of Two Different Protocols at a Single Institution","volume":"53","author":"Aoki","year":"2013","journal-title":"Neurol. Med. Chir."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"7719","DOI":"10.12659\/MSM.912999","article-title":"Renal Function and Plasma Methotrexate Concentrations Predict Toxicities in Adults Receiving High-Dose Methotrexate","volume":"24","author":"Yang","year":"2018","journal-title":"Med. Sci. Monit."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"2767","DOI":"10.1200\/JCO.2007.15.0177","article-title":"Guidelines for the Management of Pediatric and Adult Tumor Lysis Syndrome: An Evidence-Based Review","volume":"26","author":"Coiffier","year":"2008","journal-title":"J. Clin. Oncol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1111\/j.1365-2141.2010.08143.x","article-title":"Recommendations for the evaluation of risk and prophylaxis of tumour lysis syndrome (TLS) in adults and children with malignant diseases: An expert TLS panel consensus","volume":"149","author":"Cairo","year":"2010","journal-title":"Br. J. Haematol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1002\/cncr.24681","article-title":"Effect of allopurinol versus urate oxidase on methotrexate pharmacokinetics in children with newly diagnosed acute lymphoblastic leukemia","volume":"116","author":"Crews","year":"2010","journal-title":"Cancer"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"597","DOI":"10.2147\/OTT.S103864","article-title":"Prevention and treatment of tumor lysis syndrome, and the efficacy and role of rasburicase","volume":"10","author":"Alakel","year":"2017","journal-title":"Onco Targets Ther."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1097\/00045391-200501000-00005","article-title":"Pharmacokinetics and Pharmacodynamics of Febuxostat, a New Non-purine Selective Inhibitor of Xanthine Oxidase in Subjects with Renal Impairment","volume":"12","author":"Mayer","year":"2005","journal-title":"Am. J. Ther."},{"key":"ref_11","first-page":"525","article-title":"Febuxostat administration for the prevention of tumour lysis syndrome: A meta-analysis","volume":"44","author":"Bellos","year":"2019","journal-title":"J. Clin. Pharm. Ther."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"82012","DOI":"10.1155\/2007\/82012","article-title":"Tumour Lysis Syndrome Occurring in a Patient with Metastatic Gastrointestinal Stromal Tumour Treated with Glivec (Imatinib Mesylate, Gleevec, STI571)","volume":"2007","author":"Pinder","year":"2007","journal-title":"Sarcoma"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"778","DOI":"10.3748\/wjg.v16.i6.778","article-title":"A case of gouty arthritis following percutaneous radiofrequency ablation for hepatocellular carcinoma","volume":"16","author":"Choi","year":"2010","journal-title":"World J. Gastroenterol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"15030","DOI":"10.1073\/pnas.1205943109","article-title":"Putative DNA\/RNA helicase Schlafen-11 (SLFN11) sensitizes cancer cells to DNA-damaging agents","volume":"109","author":"Zoppoli","year":"2012","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Moribe, F., Nishikori, M., Sasanuma, H., Akagawa, R., Arima, H., Takeda, S., Takaori-Kondo, A., and Murai, J. (2020). Epigenetic suppression of SLFN11 in germinal center B cells in the process of the dynamic expression change during B-cell development. bioRxiv, 228650.","DOI":"10.1101\/2020.07.30.228650"},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Moribe, F., Nishikori, M., Takashima, T., Taniyama, D., Onishi, N., Arima, H., Sasanuma, H., Akagawa, R., Elloumi, F., and Takeda, S. (2021). Epigenetic suppression of SLFN11 in germinal center B-cells during B-cell development. PLoS ONE, 16.","DOI":"10.1371\/journal.pone.0237554"},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Canet, E., Zafrani, L., Lambert, J., Thieblemont, C., Galicier, L., Schnell, D., Raffoux, E., Lengline, E., Chevret, S., and Darmon, M. (2013). Acute Kidney Injury in Patients with Newly Diagnosed High-Grade Hematological Malignancies: Impact on Remission and Survival. PLoS ONE, 8.","DOI":"10.1371\/journal.pone.0055870"}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/11\/19\/5548\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T00:37:07Z","timestamp":1760143027000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/11\/19\/5548"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,22]]},"references-count":17,"journal-issue":{"issue":"19","published-online":{"date-parts":[[2022,10]]}},"alternative-id":["jcm11195548"],"URL":"https:\/\/doi.org\/10.3390\/jcm11195548","relation":{"has-preprint":[{"id-type":"doi","id":"10.20944\/preprints202207.0304.v1","asserted-by":"object"}]},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,22]]}}}